Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases
Acute Myocarditis
CardiolRx™ is currently being evaluated in a Phase II multi-national clinical study, the ARCHER trial, to evaluate the safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis – an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.
Learn More
Recurrent Pericarditis
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.
Learn More
Heart Failure
Cardiol is developing a subcutaneous formulation of cannabidiol targeting the inflammation and fibrosis associated with the development and progression of heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the U.S. exceeding $30 billion annually.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
November 14, 2022
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
TSX:CRDL NASDAQ:CRDL
